Quantcast

Latest Qiagen Stories

2014-10-29 16:28:58

VENLO, The Netherlands, October 29, 2014 /PRNewswire/ -- - Achieved Q3 2014 targets: Adjusted net sales of $336.8 million (+4% CER); adjusted operating income of $84.8 million, a 25% margin; and adjusted EPS of $0.27 - Adjusted net sales rise approximately 10% CER excluding U.S. HPV business - Growth drivers contribute about 30% of total sales, delivering more than 20% CER growth and creating solid foundation for...

2014-10-28 16:27:44

HILDEN, Germany and TOKYO, October 28, 2014 /PRNewswire/ -- - First two programs aim to create tests to aid in cancer treatment with Astellas compounds under development - QIAGEN Personalized Healthcare pipeline expands with novel assay targeting FGFR mutations - Partnership provides options for collaboration across therapeutic areas, sample types and testing technologies QIAGEN N.V. (NASDAQ: QGEN; Frankfurt...

2014-10-10 12:24:46

VENLO, The Netherlands, October 10, 2014 /PRNewswire/ -- QIAGEN N.V. (Nasdaq: QGEN) (Frankfurt: QIA) today reconfirmed plans to release its report on results for the third quarter 2014 on Wednesday, October 29, at 21:00 Central European Time (CET) / 16:00 Eastern Time (ET). On the same day, a conference call is planned at 22:00 Central European Time (CET) / 17:00 Eastern Time (ET) that will include remarks by Peer M. Schatz, President and Chief Executive Officer, and...

2014-07-31 12:28:35

DUBLIN, July 31, 2014 /PRNewswire/ -- Research and Markets has announced the addition of the "Global Genomics Market 2014-2018" report to their offering. http://photos.prnewswire.com/prnh/20130307/600769 Genomics is the study of the genetic material or genomes of an organism. It is expected to be a strong basis for the discovery and development of diagnostic and therapeutic solutions for a range of human diseases or health conditions. Genomics is supported by three major product segments:...

2014-07-29 16:26:30

VENLO, the Netherlands, July 29, 2014 /PRNewswire/ -- - Achieved Q2 2014 targets: Adjusted net sales of $331.2 million (+4% CER); adjusted operating income of $81.2 million and 25% operating margin; adjusted EPS of $0.26 CER - H1 2014 adjusted net sales rise approximately 8% CER excluding U.S. HPV tests, in line with full-year 2014 goal; H1 2014 free cash flow rises 28% to $77 million...

2014-07-28 20:24:50

LONDON, July 28, 2014 /PRNewswire/ -- Reportbuyer.com has added a new market research report:Global Genomics Market 2014-2018https://www.reportbuyer.com/product/2255162/Global-Genomics-Market-2014-2018.htmlAbout GenomicsGenomics is the study of the genetic material or genomes of an organism. It is expected to be a strong basis for the discovery and development of diagnostic and therapeutic solutions for a range of human diseases or health conditions. Genomics is supported by three...

2014-07-24 16:26:56

HILDEN, Germany, and MARSEILLE, France, July 24, 2014 /PRNewswire/ -- - Exclusive global license from University of Tokyo enables development of QIAGEN assays for SF3B1 mutations, including next-generation sequencing (NGS) gene panels, for blood cancers - Mutations of SF3B1 gene, to be targeted by new test, indicate favorable prognosis for patients with bone marrow disorders known as myelodysplastic syndromes - QIAGEN...

2014-05-23 20:21:52

GERMANTOWN, Maryland and HILDEN, Germany, May 23, 2014 /PRNewswire/ -- - Clinically proven companion diagnostic gains U.S. approval to guide use of Amgen's Vectibix(R) (panitumumab) in treatment of metastatic colorectal cancer - FDA approval (PMA) of therascreen KRAS RGQ PCR Kit for Vectibix expands QIAGEN's leadership in molecular companion diagnostics for personalized healthcare - QIAGEN driving the adoption of molecular tests...

2014-05-20 16:26:37

HILDEN, Germany and GERMANTOWN, Maryland, May 20, 2014 /PRNewswire/ -- - New biomedical content resources strengthen QIAGEN's industry-leading bioinformatics portfolio - Expansion will offer clinical researchers the most comprehensive, high-quality and up-to-date literature source for gene variant and disease phenotype associations - Expert-curated hereditary variants from HGMD are now available to customers using...

2014-05-06 16:33:13

VENLO, The Netherlands, May 6, 2014 /PRNewswire/ -- SOURCE QIAGEN N.V.


Word of the Day
maffling
  • To stammer.
  • Present participle of maffle, to stammer.
  • A simpleton.
The word 'maffle' may come from a Dutch word meaning 'to move the jaws' or a French word meaning 'having large cheeks'.